Clinical Trial Details

Overview

Research Study Summary

Type 2 Diabetes with Sulfonylureas

Purpose

This study is a 2 year study that will evaluate the effectiveness and safety of the investigational medication, Sotagliflozin.

Dosing for this study involves 2 tablets of Sotagliflozin by mouth daily or 2 tablets of placebo, which has no therapeutic effect.

To Learn more

CW ID: 224520
Date Last Changed: May 11, 2017

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
18 and up
Overall Status
Recruiting
Lead Sponsor
Sanofi US Services Inc.
Duration
2 Years
Facility Type
Out-Patient

Eligibility

To qualify you must:
  • Be 18 years of age or older
  • Have Type 2 Diabetes
  • Taking a Sulfonylurea which include: Glimiperide/Amaryl; Glipizide/Glucotrol; Blyburide/Macronase, DiaBeta, Glynase PresTab
  • Have an HbA1c between 7.0 and 10
  • Not be using insulin

More Info

Your participation in the study will be approximately 2 years long and will include up to 14 visits to the study site. Qualified participants will receive, at no charge, all study related care and evaluations including study-related doctor’s care and study medication, study related laboratory tests, and compensation for time and travel.

Contact

Customer Service
Phoenix Medical Research
9171 W Thunderbird Rd Suite 101
Peoria, AZ 85381
Phone: 623-815-9800
Fax: 623-583-6534

View Map

Research Center Information:

Phoenix Medical Research

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.